The latest update is out from Apogee Therapeutics, Inc. ( (APGE) ).
Apogee Therapeutics has revealed promising nine-month data from its Phase 1 trial of APG777, a novel antibody aimed at treating atopic dermatitis and other inflammatory diseases. The results show a potential best-in-class profile with a 75-day half-life, significantly extending the dosing period compared to current treatments. APG777 demonstrated strong inhibition of key inflammatory markers and was well-tolerated, paving the way for its Phase 2 trial. These developments highlight Apogee’s commitment to advancing effective therapies in the inflammatory and immunology markets.
Learn more about APGE stock on TipRanks’ Stock Analysis page.
